Antag Therapeutics ApS: Financial statements 2022
CVR: 38402056
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Antag Therapeutics ApS (CVR 38402056) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -9,904,462 and a net result of DKK -9,784,355 compared with DKK -14,863,343 the year before. Equity in the 2022 report amounted to DKK 4,638,803. The solvency ratio was 26.4%. The company had 2 employees in the financial year.
- Gross Profit
- DKK -9,904,462
- Profit/Loss
- DKK -9,784,355
- Equity
- DKK 4,638,803
- Total Assets
- DKK 17,563,744
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -9.9M | -9.8M | 4.6M | 2 |
| 2021 | - | -13.1M | -14.9M | 10.9M | 6 |
| 2020 | - | -10.9M | -12.4M | -9.8M | 7 |
| 2019 | - | -7.9M | -9.2M | 2.6M | 4 |
| 2018 | - | -3.1M | -4.4M | 11.8M | 4 |
Official annual report
Keep an eye on Antag Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Antag Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -13,085,955, and the net result was DKK -14,863,343.
About Antag Therapeutics ApS
Antag Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Antag Therapeutics IVS. The management consists of Philip Just Larsen. The board consists of Keith Richard Leonard Jr (chair), Alexander Volker Wilhelm Mayweg, Amit Kantilal Shah and Jørgen Søberg Petersen. The company's owners include Novo Holdings A/S, Dawn Holdco SCSp and Versant Venture Capital VII, L.P.. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -191,588,449 and a net result of DKK -200,999,582 compared with DKK -32,265,249 the year before. Equity in the 2025 report amounted to DKK 235,310.